The associations of IL-18 serum levels and promoter polymorphism with tacrolimus pharmacokinetics and hepatic allograft dysfunction in Chinese liver transplantation recipients

Gene

Volumn 491, Issue 2, 2012, Pages 251-255

  Li, Yi ^a   Zou, Yuangao ^a   Cai, Bei ^a   Yang, Bin ^a   Ying, Binwu ^a   Shi, Yunying ^a   Wang, Lanlan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Hepatic allograft dysfunction; Interleukin 18; Liver transplantation; Polymorphism; Tacrolimus pharmacokinetics

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 18; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; CHINESE; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HUMAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM;

FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-18; LIVER TRANSPLANTATION; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRIMARY GRAFT DYSFUNCTION; PROMOTER REGIONS, GENETIC; TACROLIMUS;

EID: 81555219468     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2011.10.008     Document Type: Article

References (25)

1. Belliard A.M., Tardivel S., Farinotti R., Lacour B., Leroy C. Effect of hr-IL2 treatment on intestinal P-glycoprotein expression and activity in Caco-2 cells. J. Pharm. Pharmacol. 2002, 54:1103-1109.
2. Cattaneo D., Baldelli S., Perico N. Pharmacogenetics of immunosuppressants: progress, pitfalls and promises. Am. J. Transplant. 2008, 8:1374-1383.
3. Chen D.Y., Hsieh C.W., Chen K.S., Chen Y.M., Lin F.J., Lan J.L. Association of interleukin-18 promoter polymorphisms with WHO pathological classes and serum IL-18 levels in Chinese patients with lupus nephritis. Lupus 2009, 18:29-37.
4. Dixit S.G., Zingarelli B., Buckley D.J., Buckley A.R., Pauletti G.M. Nitric oxide mediates increased P-glycoprotein activity in interferon-{gamma}-stimulated human intestinal cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G533-G540.
5. Fukudo M., Yano I., Shinsako K., Katsura T., Takada Y., Uemoto S., Inui K. Prospective evaluation of the bayesian method for individualizing tacrolimus dose early after living-donor liver transplantation. J. Clin. Pharmacol. 2009, 49:789-797.
6. Girnita D.M., Burckart G., Zeevi A. Effect of cytokine and pharmacogenomic genetic polymorphisms in transplantation. Curr. Opin. Immunol. 2008, 20:614-625.
7. Hakkola J., Hu Y., Ingelman-Sundberg M. Mechanisms of down-regulation of CYP2E1 expression by inflammatory cytokines in rat hepatoma cells. J. Pharmacol. Exp. Ther. 2003, 304:1048-1054.
8. Hartz A.M.S. Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor- and lipopolysaccharide. Mol. Pharmacol. 2005, 69:462-470.
9. Heemskerk S., Peters J.G.P., Louisse J., Sagar S., Russel F.G.M., Masereeuw R. Regulation of P-glycoprotein in renal proximal tubule epithelial cells by LPS and TNF-α. J. Biomed. Biotechnol. 2010, 2010:1-11.
10. Jover R., Bort R., Gomez-Lechon M.J., Castell J.V. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J. 2002, 16:1799-1801.
11. Kalsotra A., Anakk S., Brommer C.L., Kikuta Y., Morgan E.T., Strobel H.W. Catalytic characterization and cytokine mediated regulation of cytochrome P450 4Fs in rat hepatocytes. Arch. Biochem. Biophys. 2007, 461:104-112.
12. Khripko O.P., Sennikova N.S., Lopatnikova J.A., Khripko J.I., Filipenko M.L., Khrapov E.A., Gelfgat E.L., Yakushenko E.V., Kozlov V.A., Sennikov S.V. Association of single nucleotide polymorphisms in the IL-18 gene with production of IL-18 protein by mononuclear cells from healthy donors. Mediators Inflamm. 2008, 2008:309721.
13. Li D., Lu W., Zhu J.Y., Gao J., Lou Y.Q., Zhang G.L. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J. Clin. Pharm. Ther. 2007, 32:505-515.
14. Li D., Zhu J.Y., Gao J., Wang X., Lou Y.Q., Zhang G.L. Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Clin. Chim. Acta 2007, 383:133-139.
15. Nakanishi K., Y.T., Tsutsui H., Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol. 2001, 19:423-474.
16. Prandota J. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology. Am. J. Ther. 2005, 12:254-261.
17. Striz I., Krasna E., Honsova E., Lacha J., Petrickova K., Jaresova M., Lodererova A., Bohmova R., Valhova S., Slavcev A., Vitko S. Interleukin 18 (IL-18) upregulation in acute rejection of kidney allograft. Immunol. Lett. 2005, 99:30-35.
18. Sukhai M., Yong A., Pak A., Piquette-Miller M. Decreased expression of P-glycoprotein in interleukin-1beta and interleukin-6 treated rat hepatocytes. Inflamm. Res. 2001, 50:362-370.
19. Thervet E., Anglicheau D., Legendre C., Beaune P. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. Ther. Drug Monit. 2008, 30:143-150.
20. Thevenod F., Friedmann J.M., Katsen A.D., Hauser I.A. Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. J. Biol. Chem. 2000, 275:1887-1896.
21. Wavamunno M.D., Chapman J.R. Individualization of immunosuppression: concepts and rationale. Curr. Opin. Organ Transplant. 2008, 13:604-608.
22. Wiesner R.H., Menon K.V. Late hepatic allograft dysfunction. Liver Transpl. 2001, 7:S60-S73.
23. Zheng H., Zeevi A., Schuetz E., Lamba J., McCurry K., Griffith B.P., Webber S., Ristich J., Dauber J., Iacono A., Grgurich W., Zaldonis D., McDade K., Zhang J., Burckart G.J. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J. Clin. Pharmacol. 2004, 44:135-140.
24. Zidek Z., Anzenbacher P., Kmonickova E. Current status and challenges of cytokine pharmacology. Br. J. Pharmacol. 2009, 157:342-361.
25. Zuckermann A., Manito N., Epailly E., Fiane A., Bara C., Delgado J.F., Lehmkuhl H., Ross H., Eisen H., Chapman J., Valantine H. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J. Heart Lung Transplant. 2008, 27:141-149.